Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q14697
UPID:
GANAB_HUMAN
Alternative names:
Alpha-glucosidase 2; Glucosidase II subunit alpha
Alternative UPACC:
Q14697; A6NC20; Q8WTS9; Q9P0X0
Background:
Neutral alpha-glucosidase AB, also known as Alpha-glucosidase 2 and Glucosidase II subunit alpha, plays a pivotal role in the maturation and localization of PKD1/Polycystin-1 and PKD2/Polycystin-2 to the cell surface and cilia. It is essential in cleaving the 2 innermost alpha-1,3-linked glucose residues from the oligosaccharide precursor of immature glycoproteins, facilitating proper protein folding and function.
Therapeutic significance:
The protein's involvement in Polycystic kidney disease 3, a condition leading to end-stage renal disease, underscores its therapeutic significance. Understanding the role of Neutral alpha-glucosidase AB could open doors to potential therapeutic strategies for treating or managing this genetic disorder and possibly other related cystic diseases.